APO Research
Talk to an analyst

APO RESEARCH · REPORT

Life Science CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Life Science CDMO Market Analysis and Forecast 2026-2032

1 May 2026222 pages

Choose your research edition.

Industry ResearchLife Science CDMO Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Life Science CDMO Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Life Science CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Life Science CDMO Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Life Science CDMO Market Analysis and Forecast 2026-2032222 pages · $4,950 USD

Market perspective

The global Life Science CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Life Science CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Life Science CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Life Science CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Life Science CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Life Science CDMO include Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics, Samsung Biologics, Siegfried, Fujifilm Diosynth Biotechnologies, Lars Petersen and Recipharm, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Life Science CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Life Science CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Life Science CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Life Science CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Life Science CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Life Science CDMO revenue, projected growth trends, production technology, application and end-user industry.

Life Science CDMO Segment by Company

Lonza Group

Thermo Fisher Scientific

Catalent

WuXi Biologics

Samsung Biologics

Siegfried

Fujifilm Diosynth Biotechnologies

Lars Petersen

Recipharm

Boehringer Ingelheim

MilliporeSigma

Aenova Group

AGC Parma Chemicals

GenScript

Novartis

Sai Life Sciences

Life Science CDMO Segment by Type

Active Pharmaceutical Ingredient (API) CDMO

Biologics CDMO

Finished Dosage Form (FDF) CDMO

Others

Life Science CDMO Segment by Application

Pharmaceutical

Clinical

Research

Life Science CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Life Science CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Life Science CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Life Science CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Life Science CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Life Science CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Life Science CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Life Science CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Active Pharmaceutical Ingredient (API) CDMO Major Player Table 3. Biologics CDMO Major Player Table 4. Finished Dosage Form (FDF) CDMO Major Player Table 5. Others Major Player Table 6. Global Life Science CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Pharmaceutical Major Player Table 8. Clinical Major Player Table 9. Research Major Player Table 10. Life Science CDMO Industry Trends Table 11. Life Science CDMO Industry Drivers Table 12. Life Science CDMO Industry Opportunities and Challenges Table 13. Life Science CDMO Industry Restraints Table 14. Global Life Science CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Life Science CDMO Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Life Science CDMO Market Share by Region (2021-2026) Table 17. Global Life Science CDMO Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Life Science CDMO Market Share by Region (2027-2032) Table 19. Global Life Science CDMO Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Life Science CDMO Revenue Market Share by Players (2021-2026) Table 21. Global Life Science CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Life Science CDMO Key Players Headquarters & Area Served Table 23. Global Life Science CDMO Players, Product Type & Application Table 24. Global Life Science CDMO Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Life Science CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Life Science CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Life Science CDMO Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Life Science CDMO Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Life Science CDMO Revenue Market Share by Type (2021-2026) Table 31. Global Life Science CDMO Revenue Market Share by Type (2027-2032) Table 32. Global Life Science CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Life Science CDMO Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Life Science CDMO Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Life Science CDMO Revenue Market Share by Application (2021-2026) Table 36. Global Life Science CDMO Revenue Market Share by Application (2027-2032) Table 37. Lonza Group Company Information Table 38. Lonza Group Business Overview Table 39. Lonza Group Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Lonza Group Life Science CDMO Product Portfolio Table 41. Lonza Group Recent Development Table 42. Thermo Fisher Scientific Company Information Table 43. Thermo Fisher Scientific Business Overview Table 44. Thermo Fisher Scientific Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Thermo Fisher Scientific Life Science CDMO Product Portfolio Table 46. Thermo Fisher Scientific Recent Development Table 47. Catalent Company Information Table 48. Catalent Business Overview Table 49. Catalent Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Catalent Life Science CDMO Product Portfolio Table 51. Catalent Recent Development Table 52. WuXi Biologics Company Information Table 53. WuXi Biologics Business Overview Table 54. WuXi Biologics Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. WuXi Biologics Life Science CDMO Product Portfolio Table 56. WuXi Biologics Recent Development Table 57. Samsung Biologics Company Information Table 58. Samsung Biologics Business Overview Table 59. Samsung Biologics Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Samsung Biologics Life Science CDMO Product Portfolio Table 61. Samsung Biologics Recent Development Table 62. Siegfried Company Information Table 63. Siegfried Business Overview Table 64. Siegfried Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Siegfried Life Science CDMO Product Portfolio Table 66. Siegfried Recent Development Table 67. Fujifilm Diosynth Biotechnologies Company Information Table 68. Fujifilm Diosynth Biotechnologies Business Overview Table 69. Fujifilm Diosynth Biotechnologies Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Fujifilm Diosynth Biotechnologies Life Science CDMO Product Portfolio Table 71. Fujifilm Diosynth Biotechnologies Recent Development Table 72. Lars Petersen Company Information Table 73. Lars Petersen Business Overview Table 74. Lars Petersen Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Lars Petersen Life Science CDMO Product Portfolio Table 76. Lars Petersen Recent Development Table 77. Recipharm Company Information Table 78. Recipharm Business Overview Table 79. Recipharm Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Recipharm Life Science CDMO Product Portfolio Table 81. Recipharm Recent Development Table 82. Boehringer Ingelheim Company Information Table 83. Boehringer Ingelheim Business Overview Table 84. Boehringer Ingelheim Life Science CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Boehringer Ingelheim Life Science CDMO Product Portfolio Table 86. Boehringer Ingelheim Recent Development Table 87. MilliporeSigma Company Information Table 88. MilliporeSigma Business Overview Table 89. MilliporeSigma Life Science CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. MilliporeSigma Life Science CDMO Product Portfolio Table 91. MilliporeSigma Recent Development Table 92. Aenova Group Company Information Table 93. Aenova Group Business Overview Table 94. Aenova Group Life Science CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Aenova Group Life Science CDMO Product Portfolio Table 96. Aenova Group Recent Development Table 97. AGC Parma Chemicals Company Information Table 98. AGC Parma Chemicals Business Overview Table 99. AGC Parma Chemicals Life Science CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. AGC Parma Chemicals Life Science CDMO Product Portfolio Table 101. AGC Parma Chemicals Recent Development Table 102. GenScript Company Information Table 103. GenScript Business Overview Table 104. GenScript Life Science CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. GenScript Life Science CDMO Product Portfolio Table 106. GenScript Recent Development Table 107. Novartis Company Information Table 108. Novartis Business Overview Table 109. Novartis Life Science CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Novartis Life Science CDMO Product Portfolio Table 111. Novartis Recent Development Table 112. Sai Life Sciences Company Information Table 113. Sai Life Sciences Business Overview Table 114. Sai Life Sciences Life Science CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Sai Life Sciences Life Science CDMO Product Portfolio Table 116. Sai Life Sciences Recent Development Table 117. North America Life Science CDMO Revenue by Type (2021-2026) & (US$ Million) Table 118. North America Life Science CDMO Revenue by Type (2027-2032) & (US$ Million) Table 119. North America Life Science CDMO Revenue by Application (2021-2026) & (US$ Million) Table 120. North America Life Science CDMO Revenue by Application (2027-2032) & (US$ Million) Table 121. North America Life Science CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. North America Life Science CDMO Revenue by Country (2021-2026) & (US$ Million) Table 123. North America Life Science CDMO Revenue by Country (US$ Million) & (2027-2032) Table 124. Europe Life Science CDMO Revenue by Type (2021-2026) & (US$ Million) Table 125. Europe Life Science CDMO Revenue by Type (2027-2032) & (US$ Million) Table 126. Europe Life Science CDMO Revenue by Application (2021-2026) & (US$ Million) Table 127. Europe Life Science CDMO Revenue by Application (2027-2032) & (US$ Million) Table 128. Europe Life Science CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Europe Life Science CDMO Revenue by Country (2021-2026) & (US$ Million) Table 130. Europe Life Science CDMO Revenue by Country (US$ Million) & (2027-2032) Table 131. China Life Science CDMO Revenue by Type (2021-2026) & (US$ Million) Table 132. China Life Science CDMO Revenue by Type (2027-2032) & (US$ Million) Table 133. China Life Science CDMO Revenue by Application (2021-2026) & (US$ Million) Table 134. China Life Science CDMO Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Life Science CDMO Revenue by Type (2021-2026) & (US$ Million) Table 136. Asia Life Science CDMO Revenue by Type (2027-2032) & (US$ Million) Table 137. Asia Life Science CDMO Revenue by Application (2021-2026) & (US$ Million) Table 138. Asia Life Science CDMO Revenue by Application (2027-2032) & (US$ Million) Table 139. Asia Life Science CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Asia Life Science CDMO Revenue by Region (US$ Million) & (2021-2026) Table 141. Asia Life Science CDMO Revenue by Region (US$ Million) & (2027-2032) Table 142. SAMEA Life Science CDMO Revenue by Type (2021-2026) & (US$ Million) Table 143. SAMEA Life Science CDMO Revenue by Type (2027-2032) & (US$ Million) Table 144. SAMEA Life Science CDMO Revenue by Application (2021-2026) & (US$ Million) Table 145. SAMEA Life Science CDMO Revenue by Application (2027-2032) & (US$ Million) Table 146. SAMEA Life Science CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. SAMEA Life Science CDMO Revenue by Country (2021-2026) & (US$ Million) Table 148. SAMEA Life Science CDMO Revenue by Country (US$ Million) & (2027-2032) Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Life Science CDMO Image Figure 2. Global Life Science CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Life Science CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Active Pharmaceutical Ingredient (API) CDMO Image Figure 5. Biologics CDMO Image Figure 6. Finished Dosage Form (FDF) CDMO Image Figure 7. Others Image Figure 8. Global Life Science CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Life Science CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 10. Pharmaceutical Image Figure 11. Clinical Image Figure 12. Research Image Figure 13. Global Life Science CDMO Market Size (US$ Million) & (2021-2032) Figure 14. Global Life Science CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Life Science CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Life Science CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Life Science CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Life Science CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Life Science CDMO Revenue Market Share by Type (2021-2032) Figure 21. Global Life Science CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Life Science CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Life Science CDMO Revenue Market Share by Application (2021-2032) Figure 24. North America Life Science CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Life Science CDMO Revenue Share by Type (2021-2032) Figure 26. North America Life Science CDMO Revenue Share by Application (2021-2032) Figure 27. North America Life Science CDMO Revenue Share by Country (2021-2032) Figure 28. United States Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Life Science CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Life Science CDMO Revenue Share by Type (2021-2032) Figure 33. Europe Life Science CDMO Revenue Share by Application (2021-2032) Figure 34. Europe Life Science CDMO Revenue Share by Country (2021-2032) Figure 35. Germany Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Life Science CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Life Science CDMO Revenue Share by Type (2021-2032) Figure 45. China Life Science CDMO Revenue Share by Application (2021-2032) Figure 46. Asia Life Science CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Life Science CDMO Revenue Share by Type (2021-2032) Figure 48. Asia Life Science CDMO Revenue Share by Application (2021-2032) Figure 49. Asia Life Science CDMO Revenue Share by Region (2021-2032) Figure 50. Japan Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Life Science CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Life Science CDMO Revenue Share by Type (2021-2032) Figure 58. SAMEA Life Science CDMO Revenue Share by Application (2021-2032) Figure 59. SAMEA Life Science CDMO Revenue Share by Country (2021-2032) Figure 60. Brazil Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Life Science CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Active Pharmaceutical Ingredient (API) CDMO
  • Biologics CDMO
  • Finished Dosage Form (FDF) CDMO
  • Others
Applications
  • Pharmaceutical
  • Clinical
  • Research
Companies covered
  • Lonza Group
  • Thermo Fisher Scientific
  • Catalent
  • WuXi Biologics
  • Samsung Biologics
  • Siegfried
  • Fujifilm Diosynth Biotechnologies
  • Lars Petersen
  • Recipharm
  • Boehringer Ingelheim
  • MilliporeSigma
  • Aenova Group
  • AGC Parma Chemicals
  • GenScript
  • Novartis
  • Sai Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Life Science CDMO Market by Type
  3. 1.2.1 Global Life Science CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Active Pharmaceutical Ingredient (API) CDMO
  5. 1.2.3 Biologics CDMO
  6. 1.2.4 Finished Dosage Form (FDF) CDMO
  7. 1.2.5 Others
  8. 1.3 Life Science CDMO Market by Application
  9. 1.3.1 Global Life Science CDMO Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Pharmaceutical
  11. 1.3.3 Clinical
  12. 1.3.4 Research
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Life Science CDMO Market Dynamics
  1. 2.1 Life Science CDMO Industry Trends
  2. 2.2 Life Science CDMO Industry Drivers
  3. 2.3 Life Science CDMO Industry Opportunities and Challenges
  4. 2.4 Life Science CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Life Science CDMO Market Perspective (2021-2032)
  2. 3.2 Global Life Science CDMO Growth Trends by Region
  3. 3.2.1 Global Life Science CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Life Science CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Life Science CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Life Science CDMO Revenue by Players
  2. 4.1.1 Global Life Science CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Life Science CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Life Science CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Life Science CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Life Science CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Life Science CDMO Players, Product Type & Application
  8. 4.5 Global Life Science CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Life Science CDMO Market CR5 and HHI
  11. 4.6.3 2025 Life Science CDMO Tier 1, Tier 2, and Tier 3
5 Life Science CDMO Market Size by Type
  1. 5.1 Global Life Science CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Life Science CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Life Science CDMO Revenue Market Share by Type (2021-2032)
6 Life Science CDMO Market Size by Application
  1. 6.1 Global Life Science CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Life Science CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Life Science CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza Group
  2. 7.1.1 Lonza Group Company Information
  3. 7.1.2 Lonza Group Business Overview
  4. 7.1.3 Lonza Group Life Science CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza Group Life Science CDMO Product Portfolio
  6. 7.1.5 Lonza Group Recent Developments
  7. 7.2 Thermo Fisher Scientific
  8. 7.2.1 Thermo Fisher Scientific Company Information
  9. 7.2.2 Thermo Fisher Scientific Business Overview
  10. 7.2.3 Thermo Fisher Scientific Life Science CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Thermo Fisher Scientific Life Science CDMO Product Portfolio
  12. 7.2.5 Thermo Fisher Scientific Recent Developments
  13. 7.3 Catalent
  14. 7.3.1 Catalent Company Information
  15. 7.3.2 Catalent Business Overview
  16. 7.3.3 Catalent Life Science CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Catalent Life Science CDMO Product Portfolio
  18. 7.3.5 Catalent Recent Developments
  19. 7.4 WuXi Biologics
  20. 7.4.1 WuXi Biologics Company Information
  21. 7.4.2 WuXi Biologics Business Overview
  22. 7.4.3 WuXi Biologics Life Science CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 WuXi Biologics Life Science CDMO Product Portfolio
  24. 7.4.5 WuXi Biologics Recent Developments
  25. 7.5 Samsung Biologics
  26. 7.5.1 Samsung Biologics Company Information
  27. 7.5.2 Samsung Biologics Business Overview
  28. 7.5.3 Samsung Biologics Life Science CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Samsung Biologics Life Science CDMO Product Portfolio
  30. 7.5.5 Samsung Biologics Recent Developments
  31. 7.6 Siegfried
  32. 7.6.1 Siegfried Company Information
  33. 7.6.2 Siegfried Business Overview
  34. 7.6.3 Siegfried Life Science CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Siegfried Life Science CDMO Product Portfolio
  36. 7.6.5 Siegfried Recent Developments
  37. 7.7 Fujifilm Diosynth Biotechnologies
  38. 7.7.1 Fujifilm Diosynth Biotechnologies Company Information
  39. 7.7.2 Fujifilm Diosynth Biotechnologies Business Overview
  40. 7.7.3 Fujifilm Diosynth Biotechnologies Life Science CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Fujifilm Diosynth Biotechnologies Life Science CDMO Product Portfolio
  42. 7.7.5 Fujifilm Diosynth Biotechnologies Recent Developments
  43. 7.8 Lars Petersen
  44. 7.8.1 Lars Petersen Company Information
  45. 7.8.2 Lars Petersen Business Overview
  46. 7.8.3 Lars Petersen Life Science CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lars Petersen Life Science CDMO Product Portfolio
  48. 7.8.5 Lars Petersen Recent Developments
  49. 7.9 Recipharm
  50. 7.9.1 Recipharm Company Information
  51. 7.9.2 Recipharm Business Overview
  52. 7.9.3 Recipharm Life Science CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Recipharm Life Science CDMO Product Portfolio
  54. 7.9.5 Recipharm Recent Developments
  55. 7.10 Boehringer Ingelheim
  56. 7.10.1 Boehringer Ingelheim Company Information
  57. 7.10.2 Boehringer Ingelheim Business Overview
  58. 7.10.3 Boehringer Ingelheim Life Science CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Boehringer Ingelheim Life Science CDMO Product Portfolio
  60. 7.10.5 Boehringer Ingelheim Recent Developments
  61. 7.11 MilliporeSigma
  62. 7.11.1 MilliporeSigma Company Information
  63. 7.11.2 MilliporeSigma Business Overview
  64. 7.11.3 MilliporeSigma Life Science CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 MilliporeSigma Life Science CDMO Product Portfolio
  66. 7.11.5 MilliporeSigma Recent Developments
  67. 7.12 Aenova Group
  68. 7.12.1 Aenova Group Company Information
  69. 7.12.2 Aenova Group Business Overview
  70. 7.12.3 Aenova Group Life Science CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Aenova Group Life Science CDMO Product Portfolio
  72. 7.12.5 Aenova Group Recent Developments
  73. 7.13 AGC Parma Chemicals
  74. 7.13.1 AGC Parma Chemicals Company Information
  75. 7.13.2 AGC Parma Chemicals Business Overview
  76. 7.13.3 AGC Parma Chemicals Life Science CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AGC Parma Chemicals Life Science CDMO Product Portfolio
  78. 7.13.5 AGC Parma Chemicals Recent Developments
  79. 7.14 GenScript
  80. 7.14.1 GenScript Company Information
  81. 7.14.2 GenScript Business Overview
  82. 7.14.3 GenScript Life Science CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 GenScript Life Science CDMO Product Portfolio
  84. 7.14.5 GenScript Recent Developments
  85. 7.15 Novartis
  86. 7.15.1 Novartis Company Information
  87. 7.15.2 Novartis Business Overview
  88. 7.15.3 Novartis Life Science CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Novartis Life Science CDMO Product Portfolio
  90. 7.15.5 Novartis Recent Developments
  91. 7.16 Sai Life Sciences
  92. 7.16.1 Sai Life Sciences Company Information
  93. 7.16.2 Sai Life Sciences Business Overview
  94. 7.16.3 Sai Life Sciences Life Science CDMO Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Sai Life Sciences Life Science CDMO Product Portfolio
  96. 7.16.5 Sai Life Sciences Recent Developments
8 North America
  1. 8.1 North America Life Science CDMO Revenue (2021-2032)
  2. 8.2 North America Life Science CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Life Science CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Life Science CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Life Science CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Life Science CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Life Science CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Life Science CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Life Science CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Life Science CDMO Revenue by Country
  11. 8.6.1 North America Life Science CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Life Science CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Life Science CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Life Science CDMO Revenue (2021-2032)
  2. 9.2 Europe Life Science CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Life Science CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Life Science CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Life Science CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Life Science CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Life Science CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Life Science CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Life Science CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Life Science CDMO Revenue by Country
  11. 9.6.1 Europe Life Science CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Life Science CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Life Science CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Life Science CDMO Revenue (2021-2032)
  2. 10.2 China Life Science CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Life Science CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Life Science CDMO Revenue by Type (2027-2032)
  5. 10.3 China Life Science CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Life Science CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Life Science CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Life Science CDMO Revenue by Application (2027-2032)
  9. 10.5 China Life Science CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Life Science CDMO Revenue (2021-2032)
  2. 11.2 Asia Life Science CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Life Science CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Life Science CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Life Science CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Life Science CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Life Science CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Life Science CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Life Science CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Life Science CDMO Revenue by Country
  11. 11.6.1 Asia Life Science CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Life Science CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Life Science CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Life Science CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Life Science CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Life Science CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Life Science CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Life Science CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Life Science CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Life Science CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Life Science CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Life Science CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Life Science CDMO Revenue by Country
  11. 12.6.1 SAMEA Life Science CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Life Science CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Life Science CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst